Apoptosis-targeted therapies for cancer

Cancer Cell

Volumn 3, Issue 1, 2003, Pages 17-22

  Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; GX 01; OBLIMERSEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; TAMOXIFEN; TETROCARCIN A; TROGLITAZONE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; FAS ANTIGEN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOMA CELL; CLINICAL TRIAL; DRUG EFFECT; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038786580     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00241-6     Document Type: Review

References (37)

1. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7:2001;680-686.
2. Amundson S.A., Myers T., Scudiero D., Kitada S., Reed J.C., Fornace A.J. Jr. An informatics approach indentifying markers of chemosensitivity in human cancer cells. Cancer Res. 60:2000;6101-6110.
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:1999;155-162.
4. Byrd J.C., Kitada S., Flinn I., Aron J.L., Pearson M., Lucas D., Reed J.C. The mechanism of tumor cell clearance by Rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 99:2002;1038-1043.
5. Cartee L., Sankala H., Davis C., Smith R., Maggio S., Lin P.S., Dent P., Grant S. 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. Int. J. Oncol. 21:2002;351-359.
6. Chi K.N., Gleave M.E., Klasa R., Murray N., Bryce C., Lopes de Menezes D.E., D'Aloisio S., Tolcher A.W. A Phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7:2001;3920-3927.
7. Cryns V., Yuan Y. Proteases to die for. Genes Dev. 12:1999;1551-1570.
8. Deveraux Q.L., Reed J.C. IAP family proteins: Suppressors of apoptosis. Genes Dev. 13:1999;239-252.
9. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13:2001;555-562.
10. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:2002;808-815.
11. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
12. Green D.R., Evan G. A matter of life and death. Cancer Cell. 1:2002;19-30.
13. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
14. Huang D.C., Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell. 103:2000;839-842.
15. Ionov Y., Yamamoto H., Krajewski S., Reed J.C., Perucho M. Mutational inactivation of the pro-apoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl. Acad. Sci. USA. 97:2000;10872-10877.
16. Ito Y., Pandey P., Place A., Sporn M.B., Gribble G.W., Honda T., Kharbanda S., Kufe D. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien- 28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 11:2000;261-267.
17. Karin M., Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 3:2002;221-227.
18. Karin M., Cao Y., Greten F.R., Li Z.-W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev Cancer. 2:2002;301-310.
19. Kim Y., Suh N., Sporn M., Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277:2002;22320-22329.
20. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 6:2000;513-519.
21. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., Miyoshi I., Koeffler H.P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer in both in vitro and in vivo. Cancer Res. 58:1998;3344-3352.
22. Letai A., Bassik M., Walensky L., Sorcinelli M., Weiler S., Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:2002;183-192.
23. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mamalian biology. Cell. 104:2001;487-501.
24. Makin G., Hickman J.A. Apoptosis and cancer chemotherapy. Cell Tissue Res. 301:2000;143-152.
25. Motyka B., Korbutt G., Pinkoski M.J., Heibein J.A., Caputo A., Hobman M., Barry M., Shostak I., Sawchuk T., Holmes C.F., et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell. 103:2000;491-500.
26. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
27. Pedersen I.M., Kitada S., Schimmer A., Kim Y., Zapata J.M., Charboneau L., Rassenti L., Andreeff M., Bennett F., Sporn M., et al. The triterpenoid CDDO induces apoptosis in refractory CLL B-cells. Blood. 100:2002;2965-2972.
28. Reed J. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
29. Reed J.C. Apoptosis-based therapies. Nature Drug Disc. 1:2002;111-121.
30. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell. 108:2002;165-170.
31. Teixeira C., Reed J.C., Pratt M.A.C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907.
32. Testa J.R., Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA. 98:2001;10983-10985.
33. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
34. Tschopp J., Martinon F., Hofmann K. Apoptosis: Silencing the death receptors. Curr. Biol. 9:1999;R381-R384.
35. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
36. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17:1999;331-367.
37. Wu G., Chai J., Suber T.L., Wu J.-W., Du C., Wang X., Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature. 408:2000;1008-1012.